Krka (KRK) Q3 2025 earnings summary

Executive summary

• Product and service sales reached €1,529.1 million, up 7% year-over-year, with 94% generated outside Slovenia and 96% of product sales from exports.

• Net profit rose 15% to €323.7 million, with a net profit margin of 21.1%.

• Seventeen new products were added, including thirteen prescription pharmaceuticals.

• The share price increased 54% since year-end 2024, closing at €214.00 on 30 September 2025.

Financial highlights

• Revenue for Jan–Sep 2025 was €1,534.0 million, up 7% year-over-year.

• EBITDA grew 9% to €436.7 million; EBIT increased 10% to €367.2 million.

• Net financial result was €28.3 million, mainly from €34.0 million in net foreign exchange gains.

• Investments totaled €66.7 million, with €48.0 million in the controlling company.

• R&D expenses were €143.7 million, 9.4% of revenue.

Outlook and guidance

• Full-year 2025 sales are projected at €2,020 million, up 6% year-over-year, with net profit forecast at €383 million, up 8%.

• 2026 sales are projected at €2,132 million (+6%), with net profit at €405 million (+6%).

• Over €140 million in investments planned for 2026, mainly for production expansion.